🔎 Trials Near Me

Home › Lupus › Texas

Studi clinici su Lupus nello stato di Texas

26 studi su Lupus cercano partecipanti presso sedi nello stato di Texas.

Città nello stato di Texas

Testo ufficiale dello studio (inglese)

A Study to Evaluate the Efficacy and Safety of Dapirolizumab Pegol in Study Participants With Moderately to Severely Active Systemic Lupus Erythematosus

  • Sl0044 50738, Bellaire
  • Sl0044 50781, El Paso
  • Sl0044 50673, Fort Worth
  • e altri 6
In reclutamentoFase 3
Età 16 e oltre · Tutti i sessi · Aggiornato il 2 ott 2026 · NCT06617325

Study of Efficacy and Safety of LNP023 in Participants With Active Lupus Nephritis Class III-IV, +/- V

  • Prolato Clinical Research Center, Houston
In reclutamentoFase 2
Età da 18 a 100 · Tutti i sessi · Aggiornato il 1 ott 2026 · NCT05268289

A Study to Test Whether Different Doses of BI 3000202 Help People With Systemic Lupus Erythematosus (SLE)

  • Amarillo Center for Clinical Research, Amarillo
  • Precision Comprehensive Clinical Research Solutions - Colleyville, Colleyville
  • Precision Comprehensive Clinical Research Solutions, Euless
  • e altri 4
In reclutamentoFase 2
Età da 18 a 74 · Tutti i sessi · Aggiornato il 1 ott 2026 · NCT07409181

Phase 3 Extension Study to Evaluate Long-term Safety of Ianalumab in Participants With Systemic Lupus Erythematosus (SIRIUS-SLE Extension).

  • Novel Research LLC, Bellaire
  • Accurate Clinical Research, League City
  • Epic Medical Research, Red Oak
In reclutamentoFase 3
Età da 12 a 100 · Tutti i sessi · Aggiornato il 1 ott 2026 · NCT06133972

An Efficacy and Safety Study of Intravenous Anifrolumab to Treat Systemic Lupus Erythematosus in Pediatric Participants

  • Research Site, El Paso
  • Research Site, Houston
In reclutamentoFase 3
Età da 5 a 17 · Tutti i sessi · Aggiornato il 30 set 2026 · NCT05835310

A Study to Evaluate the Treatment Outcomes of Subcutaneous Anifrolumab in Immunosuppressant-naïve and Biologic-naïve Systemic Lupus Erythematosus

  • Research Site, Austin
  • Research Site, Baytown
  • Research Site, Colleyville
  • e altri 3
In reclutamentoFase 3
Età da 18 a 70 · Tutti i sessi · Aggiornato il 25 set 2026 · NCT07430306

A Study of Nipocalimab in Adults With Moderate to Severe Systemic Lupus Erythematosus

  • Amarillo Medical Specialists Rheumatology, Amarillo
  • Amarillo Center for Clinical Research, Amarillo
  • Arthritis and Rheumatology Research Institute, Frisco
  • e altri 5
In reclutamentoFase 3
Età da 18 a 75 · Tutti i sessi · Aggiornato il 25 set 2026 · NCT07438496

Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVO

  • UT Southwestern Simmons Cancer Center - RedBird, Dallas
  • UT Southwestern/Simmons Cancer Center-Dallas, Dallas
  • UT Southwestern/Simmons Cancer Center-Fort Worth, Fort Worth
  • e altri 2
In reclutamentoFase 1
Età 18 e oltre · Tutti i sessi · Aggiornato il 23 set 2026 · NCT03816345

Study Evaluating Safety, Tolerability, PK/PD of Surovatamig in Adult RA or SLE Participants

  • Research Site, Allen
  • Research Site, Mesquite
In reclutamentoFase 1
Età da 18 a 65 · Tutti i sessi · Aggiornato il 18 set 2026 · NCT07201558

Dose Escalation Study With Bispecific Antibodies in Adult Participants With Lupus Nephritis

  • Baylor College of Medicine, Houston
In reclutamentoFase 1
Età da 18 a 60 · Tutti i sessi · Aggiornato il 14 set 2026 · NCT06975787

A Study of Enpatoran in Participants With Cutaneous Manifestations of Lupus With or Without Systemic Disease (ELOWEN-2)

  • North Texas Center for Clinical Research, Frisco
  • Accurate Clinical Research, Humble
In reclutamentoFase 3
Età da 18 a 75 · Tutti i sessi · Aggiornato il 14 set 2026 · NCT07355218

A Phase 2, Open-Label, Single-Arm Trial of FT819 in Participants With Lupus Nephritis

  • The University of Texas Southwestern Medical Center, Dallas
In reclutamentoFase 2
Età da 12 a 70 · Tutti i sessi · Aggiornato il 14 set 2026 · NCT07570862

A Study of Enpatoran in Participants With Cutaneous Manifestations of Lupus With or Without Systemic Disease

  • Allen Arthritis, Allen
  • Arthritis and Rheumatology Research Institute PLLC, Allen
  • Arthritis Care of Texas, Corpus Christi
In reclutamentoFase 3
Età da 18 a 75 · Tutti i sessi · Aggiornato il 11 set 2026 · NCT07332481

A Study in Participants With Active Systemic Lupus Erythematosus With Inadequate Response to Glucocorticoids and ≥2 Immunosuppressants

  • Arthritis Care of Texas - Corpus Christi, Corpus Christi
  • Lone Star Arthritis & Rheumatology Associates, P.C., Denton
  • El Paso Medical Research Institute (MedResearch, Inc), El Paso
  • e altri 1
In reclutamentoStudio osservazionale
Età 16 e oltre · Tutti i sessi · Aggiornato il 3 set 2026 · NCT07175285

RESET-SLE: A Phase 1/2 Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects With Active Systemic Lupus Erythematosus

  • University of Texas MD Anderson Cancer Center, Houston
In reclutamentoFase 1/2
Età da 18 a 65 · Tutti i sessi · Aggiornato il 26 ago 2026 · NCT06121297

Obe-cel in Severe, Refractory Systemic Lupus Erythematosus (SLE) With Active Lupus Nephritis (LN)

  • Texas Transplant Institute, San Antonio
In reclutamentoFase 2
Età da 12 a 65 · Tutti i sessi · Aggiornato il 24 ago 2026 · NCT07053800

A Study to Assess Adverse Events, How the Drug Moves Through the Body and Effectiveness of Intravenous Infusions of ABBV-319 in Adult Participants With Systemic Lupus Erythematosus (SLE), Sjogren's Disease (SjD) and Rheumatoid Arthritis (RA)

  • Integrative Rheumatology of South Texas - Harlingen /ID# 276458, Harlingen
In reclutamentoFase 1
Età da 18 a 75 · Tutti i sessi · Aggiornato il 10 ago 2026 · NCT06977724

A Research Trial to Assess if Cenerimod is Efficacious and Safe to Treat Active Lupus Nephritis on Top of Regular Treatment

  • Rheumatology Care Center, PLLC, Bellaire
  • Texas Arthritis Center, El Paso
  • Novel Research, LLC., Houston
  • e altri 3
In reclutamentoFase 3
Età da 18 a 75 · Tutti i sessi · Aggiornato il 30 lug 2026 · NCT07201129

A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 2a Study With an Open-Label Extension Evaluating the Efficacy and Safety of VENT-03 in Adult Participants With Active Cutaneous Lupus Erythematosus With or Without Systemic Lupus Erythematosus

  • Investigative Site, Allen
  • Investigative Site, Arlington
  • Investigative Site, Colleyville
In reclutamentoFase 2
Età da 18 a 80 · Tutti i sessi · Aggiornato il 27 lug 2026 · NCT07260877

A Study of CLN-978, a Subcutaneously Administered CD19-directed T Cell Engager, in Subjects With Systemic Lupus Erythematosus

  • Stryde Research, Plano
  • Tranquil Clinical Research, Webster
In reclutamentoFase 1
Età da 18 a 70 · Tutti i sessi · Aggiornato il 5 giu 2026 · NCT06613360

A Phase 1/2a Study of DB-2304 in Healthy Adults and SLE/CLE Participants

  • US04-0, Irving
  • US02-0, San Antonio
In reclutamentoFase 1/2Volontari sani benvenuti
Età da 18 a 70 · Tutti i sessi · Aggiornato il 2 giu 2026 · NCT06625671

Testing of an Educational Tool for Patients With Melanoma and Pre-Existing Autoimmune Disease Who Are Candidates for Immune Checkpoint Inhibitors

  • M D Anderson Cancer Center, Houston
In reclutamentoStudio osservazionale
Età 18 e oltre · Tutti i sessi · Aggiornato il 20 mag 2026 · NCT04751396

Lupus Landmark Study: A Prospective Registry and Biorepository

  • UT Southwestern Medical Center, Dallas
In reclutamentoStudio osservazionale
Età da 18 a 110 · Tutti i sessi · Aggiornato il 15 apr 2026 · NCT05934149

Phase I/II Study of AD-PluReceptor Plus Tafasitamab-cxix and Lymphodepleting Chemotherapy in Patients With Autoimmune Disorders

  • MD Anderson Cancer Center, Houston
  • The University of Texas Health Science Center at Houston, Houston
In reclutamentoFase 1/2
Età 18 e oltre · Tutti i sessi · Aggiornato il 15 apr 2026 · NCT06434363

A Phase 1b Study of Budoprutug in Systemic Lupus Erythematosus (SLE)

  • Climb Bio Investigative Site #100104, Allen
  • Climb Bio Investigative Site #100101, San Antonio
In reclutamentoFase 1
Età da 18 a 65 · Tutti i sessi · Aggiornato il 27 mar 2026 · NCT07011043

Fonte: ClinicalTrials.gov, dati recuperati il 3 ott 2026. Ogni studio stabilisce i propri criteri di idoneità; è il team di ricerca a decidere chi può partecipare.